Skip to main content
Quest Diagnostics

Inadvertent Rare Use of Plasma Exchange in the Treatment of Upshaw-Shulman Syndrome

ASFA 2024

American Society for Aspheresis

Las Vegas, NV April 17-19, 2024

Poster presentation: Inadvertent Rare Use of Plasma Exchange in the Treatment of Upshaw-Shulman Syndrome

Authors: Joseph C, Wong ECC, Darbari D, Jacquot C, Mo Y, Makuria A, Webb J

Specialty: Oncology, Coagulation, Hematology

Related content

Conference Presentation
The First Report Of The American Society For Apheresis Focal Segmental Glomerulosclerosis Multi-Institutional Registry
Conference Presentation
Variability in total plasma volume calculations for patients with potentially challenging clinical conditions: a vignette-based investigation by the american society for apheresis allied health research subcommittee
Test FAQ
ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
Conference Presentation
Using GP1bM Activity (VWF:GPIbM) Versus Ristocetin Cofactor Activity (VWF:RCo) in von Willebrand Factor Panels
Conference Presentation
The First Report of the American Society for Apheresis Thrombotic Thrombocytopenic Purpura Multi-institutional Registry: 2019-2020

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.